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aim: To identify and characterize cancer stem cells (CSC) in glioblastoma multiforme (GBM).
Methods: Four-micrometer thick formalin-fixed paraffin-embedded GBM samples from 
six patients underwent 3,3-diaminobenzidine (DAB) and immunofluorescent (IF) immuno-
histochemical (IHC) staining for the embryonic stem cell (ESC) markers NANOG, OCT4, 
SALL4, SOX2, and pSTAT3. IF IHC staining was performed to demonstrate co-expres-
sion of these markers with GFAP. The protein expression and the transcriptional activities 
of the genes encoding NANOG, OCT4, SOX2, SALL4, and STAT3 were investigated 
using Western blotting (WB) and NanoString gene expression analysis, respectively.
results: DAB and IF IHC staining demonstrated the presence of a CSC population 
expressing NANOG, OCT4, SOX2, SALL4, and pSTAT3 with the almost ubiquitous 
presence of SOX2 and a relatively low abundance of OCT4, within GBM. The expres-
sion of NANOG, SOX2 and, pSTAT3 but, not OCT and SALL4, was confirmed by WB. 
NanoString gene analysis demonstrated transcriptional activation of NANOG, OCT4, 
SALL4, STAT3, and SOX2 in GBM.
conclusion: This study demonstrated a population of CSCs within GBM characterized 
by the expression of the CSC markers NANOG, SALL4, SOX2, pSTAT3 and OCT4 at 
the protein and mRNA levels. The almost ubiquitous presence of SOX2 and a relatively 
low abundance of OCT4 would support the putative existence of a stem cell hierarchy 
within GBM.
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inTrODUcTiOn
Glioblastoma multiforme (GBM), a grade 4 astrocytoma, is the most aggressive primary brain tumor 
with a 5-year survival of 2%, despite intensive research (1, 2) and the tumor usually recurs following 
surgical resection, radiotherapy, and chemotherapy (3, 4). This poor prognosis has been attributed 
to the initiation, propagation, and differentiation of cancer stem cells (CSCs) (3, 5, 6).
The CSC concept proposes that a cancer originates from a small population of CSCs either 
by the acquisition of mutations in normal embryonic stem cells (ESCs) or progenitor cells 
that were imbued with the abilities for uncontrolled growth and propagation (7, 8). While 
the tumorigenic CSCs are proposed to be the driving force behind tumor growth, the bulk of 
the tumor consists of non-tumorigenic cancer cells that have differentiated from these CSCs, 
leading to a vast cellular heterogeneity (8, 9). Furthermore, when exposed to certain epigenetic 
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or environmental factors, the downstream cancer cells can be 
reprogramed to acquire stem cell properties (10).
Embryonic stem cells, which were originally isolated from 
cells of the inner cell mass of an early mammalian embryo (blas-
tocyst) (11), possess the ability for perpetual propagation and 
differentiation into all cell lineages (12). ESCs and their down-
stream progenitors express a variety of characteristic proteins, 
including cell surface markers and transcription factors (13). 
CSCs in GBM bear the characteristics of ESCs by their expression 
of similar proteins, making it possible to both characterize and 
isolate CSCs in GBM (13, 14). A recent report demonstrates an 
ESC-like signature in high grade (grades 3 and 4) gliomas with 
upregulation of NANOG, KLF4, OCT4, and SOX2 proteins (15). 
Upregulation of these proteins has been correlated with poorer 
survival in both high- and low-grade gliomas (15, 16), although 
inclusion of gliomas of different grades and their analysis as a 
single entity means that this study inherently lacks the specificity 
needed for the characterization of a unique CSC population in 
GBM. A recent review points to CSCs in GBM possessing a 
hierarchy, with overlapping phenotypes expressing upstream 
(ESC) and downstream (progenitor cell) markers (17).
While many CSC markers have been associated with CSCs, 
there is evidence indicating that some proteins play a greater role 
than others in maintaining ESC capabilities. NANOG, OCT4, 
and SOX2 are transcription factors that have been proposed to 
function synergistically to maintain ESC pluripotency and self-
renewal (18). Expression of this protein trio has also been linked 
to aggressiveness of GBM, and all three are expressed in most 
gliomas (19). SALL4 is another transcription factor responsible 
for zygotic survival and ESC pluripotency (20, 21). Additionally, 
SALL4 physically interacts with NANOG and is associated with 
OCT4 and SOX2 (22, 23). pSTAT3, a signaling and transcription 
activating molecule, is also involved in ESC pluripotency (24) 
and is proposed to engender expression of other ESC-associated 
proteins such as SOX2 and SALL4 (25).
This study aimed to identify and characterize the CSC popula-
tion within GBM, using the ESC markers SOX2, OCT4, pSTAT3, 
SALL4, and NANOG at both the transcriptional and translational 
levels.
MaTerials anD MeThODs
Tissue samples
Six GBM tissue samples from three male and three female 
patients aged 42–81 (mean, 64.2) years were sourced from the 
Gillies McIndoe Research Institute Tissue Bank, and used in a 
study approved by the Central Health and Disabilities Ethics 
Committee (ref. no. 15CEN28).
histochemical and immunohistochemical 
staining
Four-micrometer thick formalin-fixed paraffin-embedded 
sections of GBM from six patients were used for hematoxylin 
and eosin staining to confirm the diagnosis of GBM by an ana-
tomical pathologist (HDB). 3,3-Diaminobenzidine (DAB) and 
immunofluorescent (IF) immunohistochemical (IHC) staining 
of these sections was then performed using the Leica Bond Rx 
auto-stainer (Leica, Nussloch, Germany) as previously described 
(26). DAB IHC staining for GFAP (cat# PA0026, Leica), NANOG 
(1:100; cat# ab80892, Abcam, Cambridge, UK), SOX2 (1:500; cat# 
PA-094, Thermo Fisher Scientific, Rockford, IL, USA), SALL4 
(1:30; cat# CM385M-16, Cell Marque, Rocklin, CA, USA), 
pSTAT3 (1:100; cat# 9145, Cell Signaling Technology, Danvers, 
MA, USA), and OCT4 (1:1000; cat# ab109183, Abcam) diluted 
with Bond™ primary antibody diluent (cat# AR9352, Leica) 
was undertaken for all GBM tissue samples. IF IHC staining 
was performed on two representative GBM tissue samples from 
the original cohort of patients included in DAB IHC staining, 
using identical primary antibodies and concentrations with an 
appropriate fluorescent secondary antibody. All IF IHC-stained 
slides were mounted using Vectashield HardSet anti-fade mount-
ing medium with 4,6-diamidino-2-phenylindole (cat# H-1500, 
Vector Laboratories, Burlingame, CA, USA).
Positive control human tissues for the primary antibodies were 
seminoma for NANOG, SALL4, and OCT4, skin for SOX2, and 
tonsil for pSTAT3. A secondary and tertiary only negative control 
staining by omitting the primary antibodies was performed on a 
GBM sample randomly selected from the original cohort of GBM 
samples used for DAB IHC staining (Figure S1 in Supplementary 
Material).
image analysis
All DAB IHC-stained slides were visualized with an Olympus 
BX53 light microscope (Tokyo, Japan) and the images were 
captured with the CellSens 2.0 software (Olympus). IF IHC 
stained-slides were viewed and the images were captured using an 
Olympus FV1200 biological confocal laser-scanning microscope 
and processed with cellSens Dimension 1.11 software using 2D 
deconvolution algorithm (Olympus).
Western Blotting
Five snap-frozen GBM samples, from the original cohort of six 
patients included in DAB IHC staining, were washed in 1× PBS 
and homogenized in RIPA buffer (cat# R0278, Sigma-Aldrich, 
St Lewis, MA, USA) supplemented with Halt™ Protease and 
Phosphatase Inhibitor Cocktail (cat# 1861281, Thermo Scientific, 
Waltham, MA, USA) and dithiothreitol (DTT) (cat# DTT-RO, 
Sigma-Aldrich). Protein was precipitated using a Calbiochem® 
ProteoExtract® Protein Precipitation Kit (cat# 539180, EMD 
Millipore Corp, Billerice, MA, USA) for 1 h at −20°C, washed 
and re-suspended in 1× Laemmli sample buffer (cat# 161-0737, 
Bio-Rad, Hercules, CA, USA) with 1% DTT. Equal amounts of 
protein were heated at 85°C and separated on Bolt™ 4–12% 
Bis–Tris Plus gels (cat# NW04120BOX, Invitrogen, Carlsbad, 
CA, USA) via electrophoresis. Separated protein was transferred 
to a nitrocellulose membrane (cat# IB23001, Life Technologies, 
Carlsbad, CA, USA) and blocked in 1× tris-buffered saline (pH 
7.4) containing 0.1% Tween-20 (TBST) containing 2% skim milk 
powder for 90 min at 4°C. Primary antibody probing for each CSC 
marker was overnight in TBST at 4°C with the following primary 
antibodies at the given concentrations: rabbit monoclonal anti-
OCT4 (1:1000; cat# ab109183, Abcam), anti-pSTAT3 (1:2000; 
cat# ab9145, Abcam), anti-SOX2 (1:5000; cat# PA1-094, Thermo 
FigUre 1 | representative image of h&e stained slides showing the presence of gBM (a) and DaB ihc-stained slides of gBM tissue demonstrating 
expression of csc markers (B–F). pSTAT3 [(B), brown] was expressed in the nuclei of tumor and endothelium of the microvessels throughout the sample. SALL4 
[(c), brown] was predominantly expressed on the nuclei of the tumor cells, and the cytoplasm of the endothelial cells lining the microvessels. SOX2 [(D), brown] 
displayed strong nuclear staining of the tumor cells, and moderate cytoplasmic staining of the endothelium of the microvessels. Nuclear expression of NANOG [(e), 
pink/red] was observed on the tumor cells, and to the lesser extent on the endothelium of the microvessels. Nuclear and cytoplasmic staining of OCT4 [(F), brown] 
was observed in few tumor cells. Cell nuclei were counterstained with hematoxylin [(a–F), blue]. Original magnification: 400X.
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Fisher, Scoresby, VIC, Australia), and anti-NANOG (1:2000; cat# 
ab47102, Abcam). Secondary antibody probing was in 1× TBST 
for 60 min at 4°C with goat anti-rabbit horseradish peroxidase 
(HRP; 1:10,000; cat# A16110, Thermo Fisher). Beta-actin anti-
body probing was performed with the iBind™ Flex device (cat# 
SLF2000, Life Technologies) using primary mouse monoclonal 
anti-β-actin (1:2000 cat# ab8226, Abcam) and secondary donkey 
anti-mouse Alexa fluor 488 (1:2000 cat# A21202, Thermo Fisher). 
Clarity Western ECL (cat# 1705061, Bio-Rad) was used as the 
substrate for visualizing HRP-detected protein bands, and the 
Chemi Doc MP Imaging System (Bio-Rad) and Image Lab 5.0 
software (Bio-Rad) were used for both HRP and fluorescent band 
detection and analysis.
Positive controls for the markers examined were NTERA2 for 
OCT4; NTERA2 and human placenta for SOX2; mouse lung and 
human liver for pSTAT3; 3T3 cell lysate for NANOG. Negative 
controls were HeLa for OCT4; human placenta for pSTAT3; SY5Y 
for NANOG. No negative tissues or lysates could be found for 
SOX2.
nanostring gene expression analysis
Total RNA was extracted from ~20 mg of six snap-frozen GBM tis-
sue from the same cohort of patients included in DAB IHC analy-
sis, using the MagJET RNA kit (cat# k2731, Thermo Scientific) 
and the Kingfisher Duo RNA extraction machine (Thermo 
Scientific). All samples were quantitated and quality controlled 
FigUre 2 | representative images of iF ihc-stained sections of gBM tissue for esc markers. SOX2 [(a), red, arrows], NANOG [(B), red, arrows], and 
pSTAT3 [(c), red, arrows] all showed nuclear expression on GFAP+ tumor cells [(a–c), green]. OCT4 [(D), red, arrows] staining was scarce and solely cytoplasmic in 
GFAP+ tumor cells. SALL4 [(e), green] and SOX2 [(e), red] were co-expressed (arrows) in the nuclei of some tumor cells, with SALL4 also staining SOX2–negative 
cells. Cell nuclei were counterstained with 4′, 6′-diamidino-2-phenylindole [(a–e), blue]. Scale bars: 20 μm.
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with the NanoDrop 2000 Spectrophotometer (Thermo Scientific) 
and the Qubit 2.0 Fluormeter (Thermo Scientific). The samples 
with A260/A230 ≥1.5 and A260/A280 ~2 were used for further 
analysis. The integrity of the RNA was assessed by New Zealand 
Genomics Ltd. (Dunedin, NZ) using Agilent 2100 BioAnalyzer 
(Agilent Technologies, Santa Clara, CA, USA). The isolated RNA 
was then subjected to NanoString nCounter™ Gene Expression 
Assay (NanoString Technologies, Seattle, WA, USA) as com-
pleted by New Zealand Genomics Ltd. (Dunedin, New Zealand), 
according to the manufacturer’s protocol. Probes for the genes 
encoding NANOG (XM_011520850.1), SOX2 (NM_003106.3), 
SALL4 (NM_020436.3), OCT4 (NM_001159542.1), and 
STAT3 (NM_139276.2) and the housekeeping gene GAPDH 
(NM_002046.3) were designed and synthesized by NanoString 
Technologies. Raw data were analyzed using nSolver™ software 
(NanoString Technologies) using standard settings and was 
normalized against the housekeeping gene.
resUlTs
histochemical and 3,3-Diaminobenzidine 
immunohistochemical staining
Hematoxylin and eosin stain (Figure 1A) confirmed the diagno-
sis of grade 4 astrocytoma on all 6 GBM samples. Positive staining 
for pSTAT3 (Figure 1B, brown), SALL4 (Figure 1C, brown), and 
SOX2 (Figure 1D, brown) was observed in tumor cells and within 
areas of endothelial proliferation. pSTAT3 showed consistent 
nuclear staining throughout the sample (Figure  1B, brown), 
and SALL4 staining was localized predominantly to the nuclei 
of tumor cells but was mostly cytoplasmic in the proliferative 
endothelium (Figure 1C, brown). SOX2 staining showed strong 
nuclear staining in tumor cells that lessened in intensity within 
areas of endothelial proliferation, with a consistent, moderate level 
of cytoplasmic staining throughout the entire sample (Figure 1D, 
brown). NANOG was localized to the nuclei of tumor cells but 
was not present in the endothelium (Figure  1E, pink). OCT4 
staining was scarce in all samples but showed differential staining 
patterns, with some cells exhibiting nuclear (Figure 1F, brown, 
left) and others cytoplasmic (Figure 1F, brown, right) staining.
Expected staining patterns for pSTAT3 (Figure S1A in 
Supplementary Material, brown), SALL4 (Figure S1B in Supple-
mentary Material, brown), SOX2 (Figure S1C in Supplementary 
Material, brown), NANOG (Figure S1D in Supplementary 
Material, brown), and OCT4 (Figure S1E in Supplemen-
tary  Material, brown) were demonstrated in the respective 
positive  controls. Staining with the omission of the primary 
antibodies in a GBM sample provided an appropriate negative 
control (Figure S1F in Supplementary Material).
immunofluorescent 
immunohistochemical staining
To investigate co-expression of the ESC markers, IF IHC stain-
ing was performed on two representative GBM samples used 
for DAB IHC staining. To identify GBM tumor cells, GFAP 
FigUre 3 | Western blots of five gBM tissue samples. OCT4 was not detected (a), pSTAT3 at ~90 kDa was found in three out of five samples (B), NANOG 
was present in all five samples with multiple bands at approximately 40 and 31 kDa (c). SOX2 was detected in four out of five samples with bands at approximately 
45 and 38 kDa (D).
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(Figures 2A–D, green) was utilized as a marker for glial cells (27, 
28). A substantial number of GFAP+ cells also expressed SOX2 
(Figure 2A, red, arrows), NANOG (Figure 2B, red, arrows), and 
pSTAT3 (Figure 2C, red, arrows) with relatively low expression of 
OCT4 (Figure 2D, red, arrow). To examine expression of SALL4, 
we counterstained the same samples for SOX2 (Figure 2E, red) 
and SALL4 (Figure 2E, green) demonstrating the expression of 
both markers in the same nuclei (Figure 2E, arrows). The vascu-
lature (Figures 2A–C, arrows) did not demonstrate expression of 
GFAP (Figures 2A–C, green), as expected, along with minimal 
expression of the aforementioned ESC markers. Images of the 
individual stains are presented in Figure S2 in Supplementary 
Material. A GBM sample used as a negative control by omitting 
the primary antibodies, demonstrated the specificity of the anti-
bodies used (data not shown).
Western Blotting
The presence of OCT4, NANOG, pSTAT3, and SOX2 in GBM 
samples was also examined by WB. OCT4 was below the detection 
level in all four GBM samples compared with NTERA2 cell lysate 
used as a positive control, which showed a band of approximately 
46 kDa (Figure 3A). pSTAT3 was expressed in three out of five 
GBM samples at ~90 kDa (Figure 3B). NANOG was present in 
three out of four GBM samples, although multiple bands were 
detected with the antibody at approximately 40 and 35  kDa 
(Figure 3C). SOX2 was detected in four out of five samples and 
multiple bands at approximately 45 and 38 kDa were observed 
(Figure 3D). WB data for SALL4 has not been included due to 
antibody difficulties involving non-specific binding (data not 
shown).
nanostring gene expression analysis
mRNA quantification was performed for NANOG, OCT4, 
SALL4, STAT3, and SOX2 to investigate the presence of tran-
scription activation of these markers in GBM. The expression 
values were normalized to that of the housekeeping gene GUSB 
and showed that all five markers were expressed in GBM samples 
(Figure 4).
FigUre 4 | relative expression of csc mrna transcripts in six 
gBM samples showing the presence of all 5 markers at varying 
levels. NANOG, OCT4, and SALL4 showed relatively low mRNA 
expression, while STAT3 and SOX2 displayed high levels of mRNA 
expression. Expression is depicted relative to the housekeeper 
GUSB.
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demonstrating spectral expression patterns for both SOX2 and 
pSTAT3 including GBM (1, 33, 34). This is further supported by 
the well recognized inter-tumor heterogenity observed in GBM, 
which potentially provides each tumor with a unique stem cell 
signature (10, 17, 35, 36). This may also account for the variation 
of the number of detected bands for NANOG and SOX2 on WB 
(Figures 3C,D). Different-sized bands may represent detection of 
different protein isoforms that have undergone post-translational 
modification (PTM). Different sized variants of NANOG have 
been identified previously with native NANOG (NANOG a) at 
34.2 kDa, NANOG b at 34.4 kDa, and NANOG c at 31.9 kDa (37). 
Furthermore, NANOG can undergo phosphorylation at several 
residues (38) and is also bound by the ubiquitin–proteasome 
system (39), both of which have the potential to alter band size 
on a WB. As PTM can alter protein function (39), the observation 
that three out of the four GBM samples analyzed contained only 
the 35 kDa variant (possibly corresponding to NANOG c with 
some PTMs, as the larger 40 kDa band in the positive 3T3 lysate 
control is likely to be NANOG a/b) indicates that the types of 
modified protein present within a tumor may be significant and 
that the presence of NANOG c in GBM may even be a predictor 
of tumor aggression.
SOX2 can also undergo phosphorylation, SUMOylation, and 
glycosylation (40, 41). Similar to NANOG, SOX2 PTMs can 
upregulate or downregulate SOX2 function, thus influencing 
stem cell function (39, 41). It is therefore conceivable that multi-
ple modified and/or isoforms of particular ESC markers may be 
present in any given tumor.
This study demonstrates relative abundance of ESC mark-
ers OCT4, SOX2, SALL4, NANOG, and pSTAT3. Our data 
indicates the possibility that different isoforms or modified 
versions of SOX2 and NANOG may exist within different GBM 
tumors, and that a particular isoform present may influence 
tumor growth and tumor aggression in specific ways, although 
this remains a topic for further study. Additionally, in contrast 
to previous studies (15,  42), IHC staining and NanoString 
analysis in our study revealed relatively low expression levels 
of OCT4 at the transcriptional activation and corresponding 
protein levels. We speculate that the relatively low number of 
cells expressing OCT4 represent the most primitive stem cell 
population within GBM and that they may potentially give rise 
to the remaining down-stream cells within the GBM tumor. 
Similarly, the almost ubiquitous abundance of SOX2 within 
GBM suggests that this marker is expressed on the more dif-
ferentiated cells reflecting SOX2 as a putative progenitor cell 
marker within the GBM samples used in this study. Further 
investigation in this area may lead to the possibility of tailor-
ing future treatment of GBM by targeting the most primitive 
OCT4 + CSC subpopulation.
Although a limitation of this study is the relatively small sam-
ple size, the novel findings we present lay a platform for future 
studies to better understand the precise role of CSCs in GBM.
ethics approval
Central Health and Disabilities Ethics Committee (ref. no. 
15CEN28).
DiscUssiOn
The CSC concept of cancer proposes that a tumor is generated 
by a small number of cells that possess the ability for indefinite 
self-renewal and differentiation into multiple cell types (7, 8). 
There is growing evidence in support of this concept, with CSCs 
being identified and characterized in many cancer types (17). The 
presence of CSCs in brain tumors was first reported by Singh et al. 
(6) and has been linked to tumor aggression and decreased life 
expectancy (8, 29). Furthermore, the presence of distinct ESC 
markers within GBM tumors has also been associated with poor 
outcomes (30–32). Activation of these protein markers in cancer 
cells imbues them with ESC characteristics such as indefinite 
self-renewal and pluripotency, and results in CSCs (17). We 
have demonstrated the expression of the ESC markers NANOG, 
SALL4, OCT4, SOX2, and pSTAT3 in GBM using DAB IHC 
staining (Figures 1A–F), WB (Figures 3A–D) and NanoString 
analysis (Figure  4). IHC staining showed the expression of all 
five ESC markers within the GBM samples examined (Figure 1), 
a finding that was corroborated by NanoString mRNA analysis in 
all six GBM samples. In this report, we have also demonstrated 
the expression of pSTAT3, NANOG, and SOX2 using WB analy-
sis. Due to improperly functioning antibodies, the presence of 
SALL4 could not be determined by WB, and this warrants further 
investigation. It is intriguing that OCT4 was below detection 
levels by WB despite being observed by both IHC staining and 
NanoString analysis.
As NanoString analysis showed relatively low transcript 
numbers for OCT4 (Figure  4) and DAB IHC staining showed 
OCT4 was expressed by very few cells within the tumor 
(Figure 1F), we infer that OCT4 was too low in abundance to 
be detected by WB. Possible reasons for this include sampling 
bias and/or relatively low levels of protein within the GBM tissues 
examined. This may in part be explained by the inherent intra-
tumor heterogenity within GBM tumors, with previous studies 
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